Sophie Béliard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5267640/publications.pdf

Version: 2024-02-01

623734 713466 14 21 644 21 citations g-index h-index papers 24 24 24 957 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes. Diabetes Care, 2015, 38, e182-e183.	8.6	146
2	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet, The, 2022, 399, 719-728.	13.7	69
3	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. JACC: Cardiovascular Imaging, 2021, 14, 2414-2424.	5.3	44
4	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2632-2640.	2.4	42
5	Effects of Bariatric Surgery on Hepatic and Intestinal Lipoprotein Particle Metabolism in Obese, Nondiabetic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2330-2337.	2.4	41
6	Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. Atherosclerosis, 2017, 257, 130-137.	0.8	34
7	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. Atherosclerosis, 2018, 277, 334-340.	0.8	33
8	Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 704-711.e2.	1.5	31
9	SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. Atherosclerosis, 2020, 306, 41-49.	0.8	30
10	Diabetes and Blood Glucose Disorders Under Anti-PD1. Journal of Immunotherapy, 2018, 41, 232-240.	2.4	27
11	Excess body weight is an independent risk factor for severe forms of COVID-19. Metabolism: Clinical and Experimental, 2021, 117, 154703.	3.4	25
12	Familial hypercholesterolemia. Current Opinion in Lipidology, 2018, 29, 65-71.	2.7	24
13	One-year impact of bariatric surgery on serum anti-Mullerian-hormone levels in severely obese women. Journal of Assisted Reproduction and Genetics, 2018, 35, 1317-1324.	2.5	20
14	The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients. Journal of Clinical Lipidology, 2016, 10, 1129-1136.e3.	1.5	19
15	Impact of bariatric surgery on apolipoprotein C-III levels and lipoprotein distribution in obese human subjects. Journal of Clinical Lipidology, 2017, 11, 495-506.e3.	1.5	14
16	Lipoprotein-apheresis in familial hypercholesterolemia: Long-term patient compliance in a French cohort. Atherosclerosis, 2018, 277, 66-71.	0.8	12
17	Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet Journal of Rare Diseases, 2021, 16, 381.	2.7	12
18	Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia. Journal of Clinical Lipidology, 2018, 12, 883-887.	1.5	7

#	Article	IF	CITATIONS
19	Myocardial fibrosis assessed by magnetic resonance imaging in asymptomatic heterozygous familial hypercholesterolemia: the cholcoeur study. EBioMedicine, 2021, 74, 103735.	6.1	6
20	Effectiveness of Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy on Lipid Levels in Type 2 Diabetes: a Meta-analysis. Journal of Gastrointestinal Surgery, 2022, 26, 1575-1584.	1.7	3
21	Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism. Journal of Clinical Lipidology, 2021, 15, 712-723.	1.5	1